Sanofi, MedImmune begin shipping flu vaccines

Sanofi ($SNY) and AstraZeneca's ($AZN) biotech unit, MedImmune, have begun shipping vaccines ahead of the fall flu season. In the U.S., MedImmune is only shipping its new quadrivalent vaccine, while Sanofi is offering both three and four-strain influenza shots. Sanofi release | MedImmune release

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.